Candriam S.C.A. Takes Position in Maze Therapeutics, Inc. $MAZE

Candriam S.C.A. acquired a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 278,167 shares of the company’s stock, valued at approximately $8,303,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Washington University raised its position in Maze Therapeutics by 33.3% in the fourth quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after purchasing an additional 70,121 shares during the period. Mass General Brigham Inc purchased a new position in shares of Maze Therapeutics during the 4th quarter worth $9,943,000. ArrowMark Colorado Holdings LLC purchased a new position in shares of Maze Therapeutics during the 3rd quarter worth $14,135,000. Boothbay Fund Management LLC increased its position in shares of Maze Therapeutics by 365.9% during the 3rd quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock worth $9,124,000 after purchasing an additional 276,345 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Maze Therapeutics during the 4th quarter worth about $13,425,000.

Insider Activity

In related news, CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00. Following the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at approximately $393,300. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the sale, the insider directly owned 10,503 shares in the company, valued at approximately $266,461.11. This trade represents a 41.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 141,470 shares of company stock worth $3,887,939. 5.30% of the stock is currently owned by company insiders.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $30.57 on Monday. The firm has a market cap of $1.69 billion, a PE ratio of -12.08 and a beta of 2.14. The stock has a fifty day moving average price of $26.62 and a 200 day moving average price of $35.31. Maze Therapeutics, Inc. has a 12-month low of $12.81 and a 12-month high of $53.65. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

MAZE has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. HC Wainwright increased their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Truist Financial dropped their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Finally, Wedbush upped their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.